Second shot at hope: early booster CAR-T therapy aims to lock out leukemia in kids
NCT ID NCT05460533
Summary
This study is testing if giving a second dose of a personalized immune cell therapy (tisagenlecleucel) early can help keep leukemia from coming back in children and young adults. It focuses on patients whose cancer returned or didn't respond to other treatments and who are already in remission after their first CAR-T dose. The main goal is to see if this early 'booster' can help the body maintain a state that fights the cancer longer, while also checking the safety of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado (Data Collection Only)
Aurora, Colorado, 80045, United States
-
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California, 90027, United States
-
Cincinnati Children's Hospital Medical Center (Data Collection Only)
Cincinnati, Ohio, 45229, United States
-
Johns Hopkins University (Data Collection Only)
Baltimore, Maryland, 21287, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Stanford University (Data Collection Only)
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.